Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: bob zagorin who wrote (29131)	8/13/1999 10:11:00 AM
From: celeryroot.com	Respond to of 32384

go2net.newsalert.com

To: bob zagorin who wrote (29131)	8/13/1999 10:41:00 AM
From: Henry Niman	Read Replies (2) \| Respond to of 32384

The news came out at a west coast conference on biotechs many weeks ago biz.yahoo.com and it was followed by a LGND press release biz.yahoo.com

To: bob zagorin who wrote (29131)	8/13/1999 9:11:00 PM
From: Cacaito	Read Replies (1) \| Respond to of 32384

businesswire.com, check Rosiglitazone news. (Avandia from SKB). It showed good effects against ulcerative colitis, this is a very interesting action of this tioglitazone. Maybe Ligand's tiolglitazone (3rd generations)will also show similar effects. Maybe.